Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination.

Abstract

The recent World Health Organization recommendation supporting single-dose of HPV vaccine will significantly reduce programmatic cost, mitigate the supply shortage, and simplify logistics, thus allowing more low- and middle-income countries to introduce the vaccine. From a programmatic perspective the durability of protection offered by a single-dose will be a key consideration. The primary objectives of the present study were to determine whether recipients of a single-dose of quadrivalent HPV vaccine had sustained immune response against targeted HPV types (HPV 6,11,16,18) at 10years post-vaccination and whether this response was superior to the natural antibody titres observed in unvaccinated women. Participants received at age 10-18years either one, two or three doses of the quadrivalent HPV vaccine. Serology samples were obtained at different timepoints up to 10years after vaccination from a convenience sample of vaccinated participants and from age-matched unvaccinated women at one timepoint. The evolution of the binding and neutralizing antibody response was presented by dose received. 10-year durability of immune responses induced by a single-dose was compared to that after three doses of the vaccine and in unvaccinated married women. The dynamics of antibody response among the single-dose recipients observed over 120months show stabilized levels 18months after vaccination for all four HPV types. Although the HPV type-specific (binding or neutralizing) antibody titres after a single-dose were significantly inferior to those after three doses of the vaccine (lower bounds of GMT ratios<0.5), they were all significantly higher than those observed in unvaccinated women following natural infections (GMT ratios: 2.05 to 4.04-fold higher). The results correlate well with the high vaccine efficacy of single-dose against persistent HPV 16/18 infections reported by us earlier at 10-years post-vaccination. Our study demonstrates the high and durable immune response in single-dose recipients of HPV vaccine at 10-years post vaccination.